Semler Scientific Appoints Renae Cormier as CFO

Semler Scientific, Inc. (SMLR), a leading developer of innovative medical products and services for evaluating and treating chronic diseases, has announced the appointment of Ms. Renae Cormier as its new Chief Financial Officer (CFO). Effective from July 10, 2023, Ms. Cormier will spearhead the company's accounting, finance, investor relations, and business strategy efforts. With a strong background in finance and accounting, Ms. Cormier is expected to shape Semler Scientific's financial strategy, enhance operational efficiency, and contribute to its continued growth and success.

‍

Record Quarterly Revenues Expected for Q2 2023

Semler Scientific is poised to achieve record-breaking revenues for the second quarter ending June 30, 2023. The impressive financial results are primarily driven by the continued sales of QuantaFlo®, a product that enables testing for peripheral arterial disease. This anticipated achievement reflects Semler Scientific's commitment to delivering high-quality medical solutions to both existing and new customers. More comprehensive financial details will be provided when the company releases its second-quarter earnings report, which is expected around August 10, 2023.

‍

Strategic Streamlining for Enhanced Operational Efficiency

In a bid to drive operational efficiency and maintain exceptional service quality, Semler Scientific has announced a strategic plan to streamline its operations. The company aims to reduce its employee headcount by approximately 30% before September 15, 2023. This proactive initiative is part of Semler Scientific's commitment to adapt to market conditions and optimize its resources effectively. The streamlining plan is expected to result in a reduction of quarterly operating expenses by approximately $1.5 million to $2.0 million, which will be realized during the fourth quarter ended December 31, 2023.

‍

Estimated Severance Costs and Financial Impact

As part of the strategic streamlining plan, Semler Scientific estimates incurring severance costs ranging from $0.7 million to $0.9 million. These one-time termination benefits will be paid by December 31, 2023. Despite the short-term financial impact, Semler Scientific expects the cost savings achieved from the reduction in employee headcount to offset these expenses. The company anticipates that the streamlined operations will lead to significant quarterly operating expense reductions, ultimately enhancing its financial performance.